Navigation Links
eFFECTOR Therapeutics' Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
Date:3/9/2017

SAN DIEGO, March 9, 2017 /PRNewswire/ -- eFFECTOR Therapeutics today announced that its lead product candidate, eFT508, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. eFT508 is a potent, highly selective inhibitor of MNK1 and MNK2, two enzymes that are critical for the growth and survival of tumors. eFFECTOR also announced that it has dosed the first subject in a Phase 1/2 clinical trial of eFT508 in patients with B-cell hematological malignancies.

"Diffuse large B-cell lymphoma is an aggressive disease for which patients badly need additional treatment options," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "We hope that eFT508, a selective translation regulator that blocks multiple oncogenic growth and proliferation pathways, as well as activates anti-tumor immunity, will prove effective in treating patients afflicted with this devastating disease."

The recently initiated trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics and antitumor activity of eFT508. The primary goals will be to establish a maximum tolerated dose and recommended dose for further evaluation and to assess preliminary efficacy of the compound. eFFECTOR is also conducting a Phase 1/2 dose escalation trial of eFT508 in patients with solid tumors.

Orphan designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States. The orphan designation of eFT508 for DLBCL provides increased access to FDA reviewers to discuss clinical trial designs, the ability to qualify for tax credits for certain clinical research costs, the ability to apply for annual grant funding, and a waiver of Prescription Drug User Fee Act filing fees, as well as the potential for seven years of U.S. marketing exclusivity if the product candidate is approved.

About eFT508
eFT508 is a potent, highly selective and orally bioavailable inhibitor of MNK1 and MNK2 being studied in patients with solid tumors and lymphoma. MNK1 and 2 are kinases acting as signal integrators at the convergence of multiple oncogenic pathways to regulate production of disease-driving proteins, including checkpoint proteins.

About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma is an aggressive form of non-Hodgkin lymphoma (NHL) that can begin in lymph nodes and areas of the body outside of the lymphatic system. DLBCL is the most common form of NHL, making up 30 percent of newly-diagnosed NHL cases each year, according to the Lymphoma Research Foundation. Due to the fast-acting and aggressive nature of the disease, DLBCL requires immediate treatment upon diagnosis.

About eFFECTOR Therapeutics
eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The company's investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR's most advanced program focuses on the development of eFT508. The company has additional selective translation regulator programs currently in discovery and development. For more information visit www.effector.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/effector-therapeutics-lead-product-candidate-eft508-receives-orphan-designation-from-fda-for-treatment-of-diffuse-large-b-cell-lymphoma-300420884.html


'/>"/>
SOURCE eFFECTOR Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. eFFECTOR Therapeutics Appoints Alana McNulty Chief Financial Officer
2. Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics Novel Small-Molecule Approach to Cancer Treatment
3. First patent issues on TAL effector technology
4. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
5. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
6. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
7. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
8. Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy
9. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
11. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Basel, Switzerland (PRWEB) , ... May 23, 2017 ... ... for R&D, celebrates this month its 20th anniversary, marking the occasion with a ... is sponsoring the meeting’s Welcome Reception and further extends an invitation to all ...
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... ... publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology ... the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Bacterial biofilms, surface ... molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum ... is in the tens of billions of dollars per year, there is currently a ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Stratevi, a ... expanded to the East Coast. It has opened an office in downtown Boston at ... are finding it increasingly more important to generate evidence on the value they provide, ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):